Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Adverse Events Following Immunisation and Global Scenario in Vaccine Pharmacovigilance


Affiliations
1 Department of Pharmacology, LN Medical College, Bhopal, Madhya Pradesh, India
2 Department of Pharmacology, Mahatma Gandhi Medical College and Research Institute, Pondicherry, India
     

   Subscribe/Renew Journal


The safety of vaccines is a high priority for vaccine manufacturers and drug regulatory bodies. Adverse event following immunization (AEFI) is an untoward, temporally associated event following immunization process which does not necessarily have a causal relationship with administration of vaccine. Vaccine pharmacovigilance relates to detection, assessment, understanding, prevention and communication of adverse events following immunization, or of any other vaccine - or immunization - related issues. AEFI aggravate public opposition to immunisation and jeopardize the effectiveness of immunisation campaigns. AEFI are of various types and may be due to programmatic errors, vaccine-induced or potentiated errors. Global vaccine pharmacovigilance systems focus on passive, active or hybrid systems, record linkage and rapid cycle analyses. The global advisory committee on vaccine safety also plays an important advisory role to WHO in vaccine pharmacovigilance. Majority of the population are however exposed to non-functional systems. Thus, a global vaccine safety data network can be useful in solving this problem. WHO AEFI reporting system contains a checklist and causality assessment criteria. It can be made more effective by acting on results of assessment tools. AEFI reporting in India is an elaborate process under the charge of the CDSCO, Ministry of Health and Family Welfare. However, capacity to detect and respond to AEFI needs improvement. A multipronged approach by WHO involving national authorities, multilateral agencies, nongovernmental and professional organizations, academia, healthcare institutions, pharmaceutical industry, lay public and media is the key to ensuring effective vaccine safety monitoring worldwide.

Keywords

AEFI, Vaccine Pharmacovigilance
Subscription Login to verify subscription
User
Notifications
Font Size


  • European Medicines Agency (EMEA). Committee for medicinal products for human use. Guideline on the conduct of pharmacovigilance for vaccines for pre- and postexposure prophylaxis against infectious diseases. London: EMEA 2009.
  • Singhal T, Amdekar YK, Agarwal RK. Adverse events following immunization. IAP Guidebook on Immunisation, IAP Committee on Immunisation 2007-08. New Delhi: Jaypee Brothers Medical Publishers, 2009:118-22
  • European vaccine manufacturers. Vaccine safety. EVM 2004.
  • Black S, Zuber P LF. Global trends and challenges in vaccine safety. Paediatric health 2009 Aug;3(4):329-35
  • World Health organisation. Adverse events following immunisation (AEFI): Causality assessment. Geneva: WHO, 2009.
  • Pharmaceutical drug manufacturers. Vaccine policy in India - All vaccines to come under DPCO.
  • The Uppsala Monitoring Center. The global intelligence network for benefits and risk in medicinal products 2008.

Abstract Views: 340

PDF Views: 0




  • Adverse Events Following Immunisation and Global Scenario in Vaccine Pharmacovigilance

Abstract Views: 340  |  PDF Views: 0

Authors

Reena Verma
Department of Pharmacology, LN Medical College, Bhopal, Madhya Pradesh, India
Kingshuk Lahon
Department of Pharmacology, Mahatma Gandhi Medical College and Research Institute, Pondicherry, India

Abstract


The safety of vaccines is a high priority for vaccine manufacturers and drug regulatory bodies. Adverse event following immunization (AEFI) is an untoward, temporally associated event following immunization process which does not necessarily have a causal relationship with administration of vaccine. Vaccine pharmacovigilance relates to detection, assessment, understanding, prevention and communication of adverse events following immunization, or of any other vaccine - or immunization - related issues. AEFI aggravate public opposition to immunisation and jeopardize the effectiveness of immunisation campaigns. AEFI are of various types and may be due to programmatic errors, vaccine-induced or potentiated errors. Global vaccine pharmacovigilance systems focus on passive, active or hybrid systems, record linkage and rapid cycle analyses. The global advisory committee on vaccine safety also plays an important advisory role to WHO in vaccine pharmacovigilance. Majority of the population are however exposed to non-functional systems. Thus, a global vaccine safety data network can be useful in solving this problem. WHO AEFI reporting system contains a checklist and causality assessment criteria. It can be made more effective by acting on results of assessment tools. AEFI reporting in India is an elaborate process under the charge of the CDSCO, Ministry of Health and Family Welfare. However, capacity to detect and respond to AEFI needs improvement. A multipronged approach by WHO involving national authorities, multilateral agencies, nongovernmental and professional organizations, academia, healthcare institutions, pharmaceutical industry, lay public and media is the key to ensuring effective vaccine safety monitoring worldwide.

Keywords


AEFI, Vaccine Pharmacovigilance

References